Company news
Skye Bioscience, Inc. (NASDAQ:SKYE) news
Every Skye Bioscience, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 14, 2026
SkyVolt Energy Signs LOI with Modular Data Center Company Nodiac.ai, Unlocking Potential Additional Revenue from strategic Existing and F...
June 18, 2026
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated i...
May 20, 2026
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 12, 2026
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 11, 2026
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
April 7, 2026
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Select...
April 2, 2026
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 10, 2026
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
March 5, 2026
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
February 17, 2026
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
February 2, 2026
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
January 29, 2026
Skye Bioscience to Present Poster at Keystone Obesity Conference
January 21, 2026
Skye Provides 2026 Corporate Outlook
January 12, 2026
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Ob...
January 5, 2026
Skye Bioscience to Participate in Upcoming Investment Conferences
November 24, 2025
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
November 10, 2025
Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain
November 5, 2025
Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025
November 5, 2025
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
October 6, 2025
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EAS...
September 19, 2025
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show ...
September 4, 2025
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
September 2, 2025
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
August 27, 2025
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
August 21, 2025
Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update
August 7, 2025
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
July 30, 2025
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the America...
June 23, 2025
Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions
June 17, 2025
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
May 19, 2025
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2025
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obe...
May 13, 2025
Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity
May 8, 2025
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
May 7, 2025
Skye Bioscience to Participate in May Investment and Medical Conferences
April 29, 2025
Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
April 15, 2025
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
April 14, 2025
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 20, 2025
Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025
March 14, 2025
Skye Bioscience to Participate in SXSW Session on Obesity
February 24, 2025
Skye Bioscience to Present at TD Cowen Health Care Conference
February 20, 2025
Skye Bioscience Announces Participation in February Conferences
February 4, 2025
Skye Bioscience Provides 2025 Look Ahead and Year in Review
January 13, 2025
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
December 19, 2024
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
November 18, 2024
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
November 14, 2024
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
November 7, 2024
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting A...
November 4, 2024
Skye Bioscience to Announce Third Quarter 2024 Results
November 1, 2024
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
October 29, 2024